Abstract
Birth defects and other adverse outcomes of pregnancy have been known since before the industrial age, but the need for guidelines to test chemicals to which pregnant women might be exposed was defined by the thalidomide tragedy in the 1950s and early 1960s. During the five decades that followed the tragedy, guidelines were written to test drugs, foods, and environmental contaminants. The guidelines were written to fulfill national needs, and then were expanded to international levels in order to streamline procedures in the expanding global economy. Multiple sets of animal guidelines were written, based on the need to simulate human experience. It was soon realized that the underlying principles were similar for all guidelines. Guidelines gradually evolved in two directions, in complexity and number of endpoints measured and in the expansion of internationally acceptable guidelines. This manuscript reviews, in chronological order, some of the milestones in the development of guidelines for animal studies and in the interpretations for safety assessment. Guidelines for long-term and short-term studies are reviewed, followed by a discussion of recently added endpoints and the future integration process for the assessment of reproductive toxicity risk.
Keywords: teratology, reproduction, Guidelines
Current Pharmaceutical Design
Title: History and Evolution of Reproductive and Developmental Toxicology Guidelines
Volume: 12 Issue: 12
Author(s): Thomas F.X. Collins
Affiliation:
Keywords: teratology, reproduction, Guidelines
Abstract: Birth defects and other adverse outcomes of pregnancy have been known since before the industrial age, but the need for guidelines to test chemicals to which pregnant women might be exposed was defined by the thalidomide tragedy in the 1950s and early 1960s. During the five decades that followed the tragedy, guidelines were written to test drugs, foods, and environmental contaminants. The guidelines were written to fulfill national needs, and then were expanded to international levels in order to streamline procedures in the expanding global economy. Multiple sets of animal guidelines were written, based on the need to simulate human experience. It was soon realized that the underlying principles were similar for all guidelines. Guidelines gradually evolved in two directions, in complexity and number of endpoints measured and in the expansion of internationally acceptable guidelines. This manuscript reviews, in chronological order, some of the milestones in the development of guidelines for animal studies and in the interpretations for safety assessment. Guidelines for long-term and short-term studies are reviewed, followed by a discussion of recently added endpoints and the future integration process for the assessment of reproductive toxicity risk.
Export Options
About this article
Cite this article as:
Collins F.X. Thomas, History and Evolution of Reproductive and Developmental Toxicology Guidelines, Current Pharmaceutical Design 2006; 12 (12) . https://dx.doi.org/10.2174/138161206776389813
DOI https://dx.doi.org/10.2174/138161206776389813 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunotherapy of Melanoma
Current Molecular Pharmacology Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer
Current Cancer Drug Targets Molecular Mechanisms and Therapeutic Application of NSAIDs and Derived Compounds in Alzheimers Disease
Current Alzheimer Research Protein-Tyrosine Phosphatase 1B (PTP1B): A Novel Therapeutic Target for Type 2 Diabetes Mellitus, Obesity and Related States of Insulin Resistance
Current Drug Targets - Immune, Endocrine & Metabolic Disorders HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Chronobiology of the Neuroimmunoendocrine System and Aging
Current Pharmaceutical Design Tyrosine Kinase Receptors Signaling Revealed by Global Expression Profiles: Implications for Cancer Biology
Current Genomics Twist-BRD4 Complex: Potential Drug Target for Basal-like Breast Cancer
Current Pharmaceutical Design Advances Towards The Discovery of GPR55 Ligands
Current Medicinal Chemistry Medical Treatment of Hirsutism in Women
Current Medicinal Chemistry Induction of CYP1A1. The AhR / DRE Paradigm Transcription, Receptor Regulation, and Expanding Biological Roles
Current Drug Metabolism Younger for Longer: Insulin Signalling, Immunity and Ageing
Current Aging Science Relationship between Proinflammatory Cytokines/Chemokines and Adipokines in Serum of Young Adults with Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets Vasoactive Intestinal Peptide Receptors: A Molecular Target in Breast and Lung Cancer
Current Pharmaceutical Design High-dose Cholecalciferol Supplementation Reducing Morning Blood Pressure in Normotensive DM1 Patients
Current Diabetes Reviews Effects of Endocrine Disruptors on Developmental and Reproductive Functions
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Matrix Metalloproteinases as Drug Targets in Preeclampsia
Current Drug Targets Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Materials Degradation in PVC Medical Devices, DEHP Leaching and Neonatal Outcomes
Current Medicinal Chemistry Endocrine Disruptors and Human Health
Mini-Reviews in Medicinal Chemistry